GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Capex-to-Operating-Income

Shanghai Henlius Biotech (HKSE:02696) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Shanghai Henlius Biotech's Capital Expenditure for the three months ended in Dec. 2023 was HK$0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was HK$215.13 Mil.

Hence, Shanghai Henlius Biotech's Capex-to-Operating-Income for the three months ended in Dec. 2023 was 0.00.


Shanghai Henlius Biotech Capex-to-Operating-Income Historical Data

The historical data trend for Shanghai Henlius Biotech's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Capex-to-Operating-Income Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - 1.40

Shanghai Henlius Biotech Quarterly Data
Dec17 Mar18 Jun18 Dec18 Mar19 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shanghai Henlius Biotech's Capex-to-Operating-Income

For the Biotechnology subindustry, Shanghai Henlius Biotech's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Capex-to-Operating-Income falls into.



Shanghai Henlius Biotech Capex-to-Operating-Income Calculation

Shanghai Henlius Biotech's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1106.296) / 789.487
=1.40

Shanghai Henlius Biotech's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 215.133
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Henlius Biotech  (HKSE:02696) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Shanghai Henlius Biotech Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech (HKSE:02696) Business Description

Traded in Other Exchanges
N/A
Address
No. 1801 Hongmei Road, 9th Floor, Innov Tower (Capitaland Building), Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Shanghai Henlius Biotech (HKSE:02696) Headlines

No Headlines